Back to News
Market Impact: 0.25
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Monte Rosa Therapeutics announced a milestone achievement associated with initiating a second Phase 2 clinical study for its VAV1-directed molecular glue degrader. The headline provides no additional details on the milestone, study, or financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GLUE0.70
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft's Big Bets on AI Start to Pay Off
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off